精选理由
美国乳腺影像学会调查215位放射科医生：半数在用FDA批准的AI检测乳腺癌，但效果未达预期，仅35%看到回召率改善。
美国乳腺影像学会（Society of Breast Imaging）对215名会员的调查显示，约半数已在临床使用FDA批准的AI乳腺癌检测工具。实际效果低于预期：仅35%的医生报告回召率降低，而59%原本期待这一改善。上述215名受访者在全部被测量指标上的反馈，均显示出相同的预期-现实落差。
原文 · Decoder
AI tools for breast cancer detection fall short of radiologists' expectations
About half of 215 surveyed members of the Society of Breast Imaging already use FDA-approved AI tools for breast cancer detection, but the results fall short of expectations. Only 35 percent report lower recall rates, while 59 percent had expected them. The gap between promise and reality runs through every category measured. The article AI tools for breast cancer detection fall short of radiologists' expectations appeared first on The Decoder .